OhAinle, M., Kerns, J. A., Li, M. M., Malik, H. S. & Emerman, M. Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4, 249–259 (2008).
Wang, X. et al. Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J. Virol. 85, 3142–3152 (2011).
Wittkopp, C. J., Adolph, M. B., Wu, L. I., Chelico, L. & Emerman, M. A single nucleotide polymorphism in human APOBEC3C enhances restriction of lentiviruses. PLoS Pathog. 12, e1005865 (2016).
Harris, R. S. & Dudley, J. P. APOBECs and virus restriction. Virology https://doi.org/10.1016/j.virol.2015.03.012 (2015).
Mariani, R. et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114, 21–31 (2003).
Harris, R. S. et al. DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803–809 (2003).
Yu, Q. et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11, 435–442 (2004).
Chelico, L., Pham, P. & Goodman, M. F. Mechanisms of APOBEC3G-catalyzed processive deamination of deoxycytidine on single-stranded DNA. Nat. Struct. Mol. Biol. 16, 454–455 (2009).
Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646–650 (2002).
Stopak, K., de Noronha, C., Yonemoto, W. & Greene, W. C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12, 591–601 (2003).
Sheehy, A. M., Gaddis, N. C. & Malim, M. H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9, 1404–1407 (2003).
Feng, Y., Baig, T. T., Love, R. P. & Chelico, L. Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front. Microbiol. 5, 450 (2014).
Olson, M. E., Harris, R. S. & Harki, D. A. APOBEC enzymes as targets for virus and cancer therapy. Cell Chem. Biol. 25, 36–49 (2018).
Belanger, K., Savoie, M., Rosales Gerpe, M. C., Couture, J. F. & Langlois, M. A. Binding of RNA by APOBEC3G controls deamination-independent restriction of retroviruses. Nucleic Acids Res. 41, 7438–7452 (2013).
Holmes, R. K., Malim, M. H. & Bishop, K. N. APOBEC-mediated viral restriction: not simply editing. Trends Biochem. Sci. 32, 118–128 (2007).
Pollpeter, D. et al. Deep sequencing of HIV-1 reverse transcripts reveals the multifaceted antiviral functions of APOBEC3G. Nat. Microbiol. 3, 220–233 (2018).
Newman, E. N. et al. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15, 166–170 (2005).
Iwatani, Y. et al. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35, 7096–7108 (2007).
Bishop, K. N., Verma, M., Kim, E. Y., Wolinsky, S. M. & Malim, M. H. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4, e1000231 (2008).
Mangeat, B. et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99–103 (2003).
Belanger, K. & Langlois, M. A. RNA-binding residues in the N-terminus of APOBEC3G influence its DNA sequence specificity and retrovirus restriction efficiency. Virology 483, 141–148 (2015).
Luo, K. et al. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81, 7238–7248 (2007).
Wang, X. et al. The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication. J. Virol. 86, 3777–3786 (2012).
Wu, X. et al. Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J. Virol. 73, 2126–2135 (1999).
Mbisa, J. L., Bu, W. & Pathak, V. K. APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J. Virol. 84, 5250–5259 (2010).
Mbisa, J. L. et al. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81, 7099–7110 (2007).
Raghavendra, N. K. et al. Identification of host proteins associated with HIV-1 preintegration complexes isolated from infected CD4+ cells. Retrovirology 7, 66 (2010).
Lusic, M. & Siliciano, R. F. Nuclear landscape of HIV-1 infection and integration. Nat. Rev. Microbiol. 15, 69–82 (2017).
Maertens, G. et al. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J. Biol. Chem. 278, 33528–33539 (2003).
Cherepanov, P. et al. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem. 278, 372–381 (2003).
Cherepanov, P. et al. Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nat. Struct. Mol. Biol. 12, 526–532 (2005).
Sowd, G. A. et al. A critical role for alternative polyadenylation factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin. Proc. Natl Acad. Sci. USA 113, E1054–E1063 (2016).
Maskell, D. P. et al. Structural basis for retroviral integration into nucleosomes. Nature 523, 366–369 (2015).
Kirk, P. D., Huvet, M., Melamed, A., Maertens, G. N. & Bangham, C. R. Retroviruses integrate into a shared, non-palindromic DNA motif. Nat. Microbiol. 2, 16212 (2016).
Cohn, L. B. et al. HIV-1 integration landscape during latent and active infection. Cell 160, 420–432 (2015).
McAllister, R. G. et al. Lentivector integration sites in ependymal cells from a model of metachromatic leukodystrophy: non-B DNA as a new factor influencing integration. Mol. Ther. Nucleic Acids 3, e187 (2014).
Ho, P. S. The non-B-DNA structure of d(CA/TG)n does not differ from that of Z-DNA. Proc. Natl Acad. Sci. USA 91, 9549–9553 (1994).
van Holde, K. & Zlatanova, J. Unusual DNA structures, chromatin and transcription. Bioessays 16, 59–68 (1994).
Bacolla, A. & Wells, R. D. Non-B DNA conformations, genomic rearrangements, and human disease. J. Biol. Chem. 279, 47411–47414 (2004).
Wells, R. D. Non-B DNA conformations, mutagenesis and disease. Trends Biochem. Sci. 32, 271–278 (2007).
Burdick, R. C., Hu, W. S. & Pathak, V. K. Nuclear import of APOBEC3F-labeled HIV-1 preintegration complexes. Proc. Natl Acad. Sci. USA 110, E4780–E4789 (2013).
Huthoff, H., Autore, F., Gallois-Montbrun, S., Fraternali, F. & Malim, M. H. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 5, e1000330 (2009).
Gorle, S. et al. Computational model and dynamics of monomeric full-length APOBEC3G. ACS Cent. Sci. 3, 1180–1188 (2017).
Lavens, D. et al. Definition of the interacting interfaces of Apobec3G and HIV-1 Vif using MAPPIT mutagenesis analysis. Nucleic Acids Res. 38, 1902–1912 (2010).
Shlyakhtenko, L. S. et al. Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J. Biol. Chem. 286, 3387–3395 (2011).
Vandergeeten, C. et al. Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J. Virol. 88, 12385–12396 (2014).
Belanger, K. & Langlois, M. A. Comparative analysis of the gene-inactivating potential of retroviral restriction factors APOBEC3F and APOBEC3G. J. Gen. Virol. https://doi.org/10.1099/vir.0.000214 (2015).
Alce, T. M. & Popik, W. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 279, 34083–34086 (2004).
Cen, S. et al. The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 279, 33177–33184 (2004).
Ciuffi, A. & Barr, S. D. Identification of HIV integration sites in infected host genomic DNA. Methods 53, 39–46 (2011).
Cattoglio, C. et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 110, 1770–1778 (2007).
Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: a sequence logo generator. Genome Res. 14, 1188–1190 (2004).
Schneider, T. D. & Stephens, R. M. Sequence logos: a new way to display consensus sequences. Nucleic Acids Res. 18, 6097–6100 (1990).
Battivelli, E. et al. Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4(+) T cells. Elife https://doi.org/10.7554/eLife.34655 (2018).
Soto-Giron, M. J. & Garcia-Vallejo, F. Changes in the topology of gene expression networks by human immunodeficiency virus type 1 (HIV-1) integration in macrophages. Virus Res. 163, 91–97 (2012).
Symons, J., Cameron, P. U. & Lewin, S. R. HIV integration sites and implications for maintenance of the reservoir. Curr. Opin. HIV AIDS 13, 152–159 (2018).
Ciuffi, A. & Bushman, F. D. Retroviral DNA integration: HIV and the role of LEDGF/p75. Trends Genet. 22, 388–395 (2006).
Schroder, A. R. et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521–529 (2002).
Maldarelli, F. et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179–183 (2014).
Achuthan, V. et al. Capsid-CPSF6 interaction licenses nuclear HIV-1 trafficking to sites of viral DNA integration. Cell Host Microbe 24, 392–404 e398 (2018).
Singh, P. K. et al. LEDGF/p75 interacts with mRNA splicing factors and targets HIV-1 integration to highly spliced genes. Genes Dev. 29, 2287–2297 (2015).
Marshall, H. M. et al. Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS ONE 2, e1340 (2007).
Shun, M. C. et al. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev. 21, 1767–1778 (2007).
Ciuffi, A. et al. A role for LEDGF/p75 in targeting HIV DNA integration. Nat. Med. 11, 1287–1289 (2005).
Kim, E. Y. et al. Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection. PLoS Pathog. 10, e1004281 (2014).
Cuevas, J. M., Geller, R., Garijo, R., Lopez-Aldeguer, J. & Sanjuan, R. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol. 13, e1002251 (2015).
Sato, K. et al. APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model. PLoS Pathog. 10, e1004453 (2014).
Sadler, H. A., Stenglein, M. D., Harris, R. S. & Mansky, L. M. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J. Virol. 84, 7396–7404 (2010).
Chen, H. C., Martinez, J. P., Zorita, E., Meyerhans, A. & Filion, G. J. Position effects influence HIV latency reversal. Nat. Struct. Mol. Biol. 24, 47–54 (2017).
Vranckx, L. S. et al. LEDGIN-mediated inhibition of integrase-LEDGF/p75 interaction reduces reactivation of residual latent HIV. EBioMedicine 8, 248–264 (2016).
Marini, B. et al. Nuclear architecture dictates HIV-1 integration site selection. Nature 521, 227–231 (2015).
Jiang, J. C. & Upton, K. R. Human transposons are an abundant supply of transcription factor binding sites and promoter activities in breast cancer cell lines. Mob. DNA 10, 16 (2019).
Schmitz, J. SINEs as driving forces in genome evolution. Genome Dyn. 7, 92–107 (2012).
Kondo, Y. & Issa, J. P. Enrichment for histone H3 lysine 9 methylation at Alu repeats in human cells. J. Biol. Chem. 278, 27658–27662 (2003).
Bochman, M. L., Paeschke, K. & Zakian, V. A. DNA secondary structures: stability and function of G-quadruplex structures. Nat. Rev. Genet. 13, 770–780 (2012).
Brazda, V., Laister, R. C., Jagelska, E. B. & Arrowsmith, C. Cruciform structures are a common DNA feature important for regulating biological processes. BMC Mol. Biol. 12, 33 (2011).
Jain, A., Magistri, M., Napoli, S., Carbone, G. M. & Catapano, C. V. Mechanisms of triplex DNA-mediated inhibition of transcription initiation in cells. Biochimie 92, 317–320 (2010).
Verma, A., Yadav, V. K., Basundra, R., Kumar, A. & Chowdhury, S. Evidence of genome-wide G4 DNA-mediated gene expression in human cancer cells. Nucleic Acids Res. 37, 4194–4204 (2009).
Tornaletti, S., Park-Snyder, S. & Hanawalt, P. C. G4-forming sequences in the non-transcribed DNA strand pose blocks to T7 RNA polymerase and mammalian RNA polymerase II. J. Biol. Chem. 283, 12756–12762 (2008).
Belotserkovskii, B. P. et al. A triplex-forming sequence from the human c-MYC promoter interferes with DNA transcription. J. Biol. Chem. 282, 32433–32441 (2007).
Siddiqui-Jain, A., Grand, C. L., Bearss, D. J. & Hurley, L. H. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc. Natl Acad. Sci. USA 99, 11593–11598 (2002).
Maher, L. J. 3rd, Dervan, P. B. & Wold, B. Analysis of promoter-specific repression by triple-helical DNA complexes in a eukaryotic cell-free transcription system. Biochemistry 31, 70–81 (1992).
Delic, J., Onclercq, R. & Moisan-Coppey, M. Inhibition and enhancement of eukaryotic gene expression by potential non-B DNA sequences. Biochem. Biophys. Res. Commun. 181, 818–826 (1991).
Waga, S., Mizuno, S. & Yoshida, M. Chromosomal protein HMG1 removes the transcriptional block caused by the cruciform in supercoiled DNA. J. Biol. Chem. 265, 19424–19428 (1990).
Waga, S., Mizuno, S. & Yoshida, M. Nonhistone protein HMG1 removes the transcriptional block caused by left-handed Z-form segment in a supercoiled DNA. Biochem. Biophys. Res. Commun. 153, 334–339 (1988).
Renner, T. M., Belanger, K., Goodwin, L. R., Campbell, M. & Langlois, M. A. Characterization of molecular attributes that influence LINE-1 restriction by all seven human APOBEC3 proteins. Virology 520, 127–136 (2018).
Longo, P. A., Kavran, J. M., Kim, M. S. & Leahy, D. J. Transient mammalian cell transfection with polyethylenimine (PEI). Methods Enzymol. 529, 227–240 (2013).
Cer, R. Z. et al. Non-B DB v2.0: a database of predicted non-B DNA-forming motifs and its associated tools. Nucleic Acids Res. 41, D94–D100 (2013).
Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792–1797 (2004).
Capella-Gutierrez, S., Silla-Martinez, J. M. & Gabaldon, T. trimAl: a tool for automated alignment trimming in large-scale phylogenetic analyses. Bioinformatics 25, 1972–1973 (2009).
Morrison, C. S. et al. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS 24, 573–582 (2010).
I have been writing professionally for over 20 years and have a deep understanding of the psychological and emotional elements that affect people. I’m an experienced ghostwriter and editor, as well as an award-winning author of five novels.